Irina Velikyan, Ph.D.
Irina Velikyan is an Associate Professor in Biomedical Radiation Sciences, Department of Oncology, Radiology and Radiation Sciences, Uppsala University, and she works as a scientist at PET Centre, Centre for Medical Imaging, Uppsala University Hospital. The focus of her scientific activity is development and clinical implementation of 68Ga-based radiopharmaceuticals for PET diagnostic imaging as well as bridging molecular imaging and therapy for personalized patient treatment.
Mr. Anderson has over 25 years of experience in the life sciences industry and serves as a director of PLx Pharma and Halsa Pharmaceuticals, Inc. and as an advisor to other companies in the life sciences industry. He has served as Chairman of the Board for Nanospectra Biosciences, Inc. (2003-2013) and Plx Pharma, Inc. (2005-2011). He was formerly the President and CEO of MithraGen and the Chief Operating Officer and a director of Tanox, joining Tanox in 1987 as Vice President of Corporate Development. At Tanox, he was a member of the steering committee overseeing development of Tanox’s anti-IgE products, including Xolair, a first in class treatment for asthma. From 1977 to 1987, Mr. Anderson was engaged in the private practice of law, with a focus in the areas of mergers and acquisitions, financing transactions and intellectual property licensing.
Michael Bonderer has been a Director of RadioMedix since 2009 and is a private investor. Mr. Bonderer was Managing Member of Networks Holdings, LLC, a company formed to invest in defense/aerospace application precision component manufacturing businesses, from 1994 to 2000. Mr. Bonderer has extensive capital markets experience at a variety of firms having been a founding member of The First Boston Corporation’s Mortgage Products Group, which did pioneering work in mortgage securitization and Interest Rate Swap structure and trading. Additionally, Mr. Bonderer’s capital markets experience includes having been responsible for Security Pacific Bank’s US Agency securities desk as part of their Primary Dealer operations.
Mr. Bonderer is formerly a Director and Executive Officer of Chatsworth, California based Networks Electronic Corp. Networks was a defense/aerospace application precision maker comprised an aerospace application precision plain bearings division and a defense application design and manufacturing division of miniature pyrotechnic based ordinance devices and glass-to-metal hermetic seals. Mr. Bonderer studied economics and finance as an undergraduate and fulfilled and completed Bachelor Science requirements at the University of Southern California and did work under classical and supply-side economist Arthur B. Laffer.
Jennifer Sims-Mourtada, Ph.D.
Jennifer Sims-Mourtada, Ph.D., is a cofounder of RadioMedix. She is currently a senior clinical scientist for the Center for Translational Cancer Research, Helen F. Graham Cancer Center at Christiana Care Health System. She holds a faculty affiliation at the University of Delaware. Prior to joining HFGCC, she served as Director of Molecular Research and Development at RadioMedix. Dr. Sims-Mourtada’s research focuses on identifying markers to help predict how aggressively cancer may progress in individual patients. The findings could potentially help doctors diagnose and monitor cancer through less invasive scans instead of surgery and biopsies and provide more personalized treatments that may reduce the likelihood of metastatic disease and provide better outcomes. Dr. Sims-Mourtada earned her doctorate in biomedical sciences in 2004 from University of Texas Graduate School of Biomedical Sciences in Houston. She completed her post-doctoral fellowship in the Department of Experimental Radiation Oncology at the University of Texas M.D. Anderson Cancer Center in Houston. She serves as a reviewer for NIH and several journals in her field and has published numerous papers on her research.